Compare Mesoblast Limited (MESO) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Mesoblast Limited trades at $16.25 (market cap $2.17B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.41. The key difference: Mesoblast Limited is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| MESO | TMF | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $20.96 | $44.14 |
52-Week Low | $12.88 | $31.85 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $32.66, down 2.07% on the day, reflecting a bearish technical trend with moving averages signaling sell pressure. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights its significant long-term decline, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields and Federal Reserve policy. While some analysts see potential at the lower end of the trading range, the fund's structure makes it unsuitable for long-term holding due to volatility decay. Key risks include rising interest rates, inflation expectations, and the inherent leverage mechanism that amplifies losses. It remains a high-risk, tactical instrument for short-term traders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
